This is now the third anti-viral therapy to disappoint us within a few weeks (preliminary data on lopinavir/ritonavir and remdesivir were both unimpressive). This raises a question of whether any anti-viral therapies will be beneficial. Especially among the critically ill, patients often present relatively late (at a time-point when viral load is already falling anyway). Much of the pathogenesis of critical illness seems to result from dysregulated inflammation, rather than direct viral cytopathic effect. This raises a question of whether any antiviral treatment will be beneficial for late-presenting patients with severe illness.